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Abstract
Background—Infants are at greatest risk for severe pertussis. In 2006, the Advisory Committee 
on Immunization Practices recommended that adolescents and adults, especially those with infant 
contact, receive a single dose of Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular 
pertussis vaccine). To assess the effectiveness of cocooning, we conducted a case-control 
evaluation of infant close contacts.
Methods—Pertussis cases aged <2 months with onset between 1 January 2011 and 31 December 
2011 were identified in Emerging Infections Program Network sites. For each case, we recruited 3 
controls from birth certificates and interviewed identified adult close contacts (CCs) or parents of 
CCs aged <18 years. Pertussis vaccination was verified through medical providers and/or 
immunization registries.
Results—Forty-two cases were enrolled, with 154 matched controls. Around enrolled infants, 
859 CCs were identified (600 adult and 259 nonadult). An average of 5.4 CCs was identified per 
case and 4.1 CCs per control. Five hundred fifty-four (64.5%) CCs were enrolled (371 adult and 
183 non-adult CCs); 119 (32.1% of enrolled) adult CCs had received Tdap. The proportion of 
Tdap-vaccinated adult CCs was similar between cases and controls (P = .89). The 600 identified 
adult CCs comprised 172 potential cocoons; 71 (41.3%) potential cocoons had all identified adult 
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CCs enrolled. Of these, 9 were fully vaccinated and 43.7% contained no Tdap-vaccinated adults. 
The proportion of fully vaccinated case (4.8%) and control (10.0%) cocoons was similar (P = .43).
Conclusions—Low Tdap coverage among adult CCs reinforces the difficulty of implementing 
the cocooning strategy and the importance of vaccination during pregnancy to prevent infant 
pertussis.
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Reported pertussis incidence has been increasing in the United States since the 1990s, with 
significant epidemic peaks occurring in recent years. The greatest morbidity and mortality 
from pertussis is observed among infants, especially during the first few months of life. 
Approximately half of infants <1 year of age who are diagnosed with pertussis will be 
hospitalized, and 1 in 100 hospitalized infant cases will die as a result of their infection [1]. 
Between 2000 and 2011, approximately 14 604 pertussis hospitalizations and 215 pertussis 
deaths were reported in the United States among infants <1 year of age [1]. When a source 
of pertussis infection can be identified, parents, siblings, or other infant caregivers are 
typically responsible for transmitting the disease to vulnerable infants [2–5].
In the United States, the recommended childhood immunization schedule includes 5 doses 
of diphtheria toxoid, tetanus toxoid, and acellular pertussis (DTaP) vaccine beginning at 2 
months of age, which leaves young infants unprotected against disease during the first 
months of life [6]. In 2005, 2 tetanus toxoid, reduced diphtheria toxoid, and acellular 
pertussis (Tdap) vaccines were licensed for routine use among adolescents and adults. The 
Advisory Committee on Immunization Practices (ACIP) recommended in 2006 that all 
adolescents and adults be vaccinated with a single dose of Tdap, emphasizing the 
importance of vaccinating adults in close contact with young infants [7, 8]. This strategy 
targets mothers, fathers, and other infant caregivers for vaccination to create a protective 
“cocoon” around vulnerable infants, with the goal of interrupting pertussis transmission 
from infected adults.
While recommendations for Tdap cocooning have been in place since 2006, implementation 
of the strategy has posed many challenges [9–11]. Logistically, infant close contacts are 
usually targeted during the postpartum hospital stay, a period typically lasting no more than 
a few days. This may require additional hospital staffing resources for patient education and 
Tdap administration. Additionally, hospitals may be unable to provide vaccine to 
nonpatients, forcing the referral of family members to outside locations for vaccination and 
decreasing the likelihood of compliance. The cost of vaccines is also an important 
consideration. Cocooning programs offering free vaccine have had better success, but must 
ensure continued funding; for programs that do not offer free vaccine, billing and 
reimbursement challenges are a reality [11]. When cocooning has been successfully 
implemented, it has generally been limited to single institutions where there is an 
immunization champion and where a substantial investment of resources has been made [11, 
12].
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We conducted a case-control evaluation among infant pertussis cases <2 months of age to 
evaluate the ACIP-recommended Tdap cocooning strategy.
METHODS
Infants <2 months of age who were diagnosed with confirmed or probable pertussis 
according to the Council of State and Territorial Epidemiologists (CSTE) pertussis case 
definition and had cough onset between 1 January 2011 and 31 December 2011 were 
identified through routine surveillance in 6 Emerging Infections Program Network sites 
including Connecticut (statewide), Minnesota (statewide), New Mexico (statewide), New 
York (33 counties), and Oregon (3 counties); case identification in California (statewide) 
was limited to those cases with cough onset between 1 July 2011 and 31 December 2011. At 
the time of the evaluation, CSTE defined a confirmed pertussis case as cough illness of any 
duration with isolation of Bordetella pertussis from a clinical specimen, or cough illness of ≥ 
2 weeks with at least 1 pertussis symptom (paroxysmal cough, inspiratory “whoop,” 
posttussive vomiting) and polymerase chain reaction (PCR) positive for pertussis, or epi-
linkage to a laboratory-confirmed case and cough illness of ≥ 2 weeks with at least 1 
pertussis symptom [13]. A probable case was defined as cough illness of ≥ 2 weeks with at 
least 1 pertussis symptom (paroxysmal cough, inspiratory “whoop,” posttussive vomiting) in 
the absence of laboratory confirmation. Infants who were PCR positive for pertussis and had 
a cough illness of any duration were also eligible for enrollment in the evaluation.
Identified cases were eligible for enrollment if they were at least 2 days of age and resided in 
the catchment area on date of cough onset, were born in a hospital in their state of residence, 
were ≥ 37 weeks gestational age at birth, were not adopted or in foster care, and did not 
reside in an institution or nonresidential facility. For each eligible case, project personnel 
attempted to recruit 3 controls from birth certificate records that were born at the same 
hospital as the case and were <2 months of age on the date of the matched case’s cough 
onset. Control infants had the same eligibility criteria as cases, but were additionally 
considered ineligible if they had been diagnosed with pertussis prior to the corresponding 
case cough onset date.
Mothers of enrolled case and control infants were interviewed by phone to collect 
information on demographic characteristics, relationship to and amount of time spent with 
the case or control infant, recent vaccinations and medical providers, and to identify 
household contacts and caregivers of the case or control infant. The reference period was 
defined as the 30-day period prior to case cough onset date. Infant close contacts were 
defined as people who stayed overnight in the same household as the case or control infant ≥ 
50% of time during the reference period or provided care to the infant including changing 
diapers and clothing, feeding, bathing, taking on walks, playing, etc. Identified close 
contacts who were <18 years of age at time of interview and whose parent/guardian was not 
the same as the case or control infant’s parent/guardian, who had no contact with the infant 
during the reference period, or who resided outside the United States at the time of interview 
were not eligible for enrollment. Eligible adult close contacts were interviewed to collect 
demographic characteristics, relationship to and amount of time spent with the case or 
control infant, medical providers, and Tdap vaccination history; identified close contacts <18 
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years of age were not interviewed, but their relationship to and the amount of time spent 
with the case or control infant and information on pertussis vaccination history was collected 
through interview of their parent/guardian.
Project personnel collected pertussis vaccination status of all eligible close contacts through 
medical providers and/or state immunization registries. When complete pertussis vaccine 
history was not available in the state immunization registry, all medical providers identified 
by the close contact during the interview were contacted. Birth hospitals of the case or 
control infant were also contacted to obtain maternal Tdap history. A dose of Tdap was 
considered valid if received at least 2 weeks before the case infant’s cough onset date; for 
controls, the date of cough onset for the matched case infant was used. A close contact was 
considered enrolled if both the interview and vaccine history follow-up were completed. 
Complete enrollment around an infant was achieved when all identified adult close contacts 
were enrolled; because Tdap is routinely recommended for adolescents at 11–12 years of 
age and the cocooning strategy’s primary focus is vaccinating adults who will have close 
contact with an infant, close contacts aged <18 years were not considered for completeness.
Data analysis was performed using SAS software version 9.3. Differences between 
proportions were evaluated using Co-chran-Mantel-Haenszel statistics; differences between 
means were tested using Student t test. A P value of <.05 was considered statistically 
significant.
RESULTS
During the evaluation period, 90 cases were identified, resulting in 42 (46.7%) enrolled 
cases and 154 matched controls. Of the 48 cases that were not enrolled, 5 (10.4%) were 
ineligible, 7 (14.6%) refused, and 36 (75.0%) could not be reached. Among the 196 enrolled 
case and control infants, 859 individual close contacts were identified (Figure 1). Overall, an 
average of 5.4 (range, 1–10) and 4.1 (range, 1–11) close contacts was identified per enrolled 
case and per enrolled control, respectively (P = .0018). When identified close contacts were 
stratified by age group, significant differences were observed between case and control 
infants in the average number of identified close contacts <18 years of age (2.3 close 
contacts per case vs 1.7 close contacts per control; P = .0037), but not close contacts ≥ 18 
years of age (3.4 close contacts per case vs 3.0 close contacts per control; P = .0616).
Overall, the relationship of identified close contacts to the infant was most frequently 
siblings (24.7%) or mothers (23.1%) (Figure 2). No differences were observed in the 
proportion of close contacts identified as siblings (P = .85) or mothers (P = .11) between 
case and control infants. Close contacts were more frequently identified as fathers among 
control infants (21.3% for controls vs 14.7% for cases; P = .0327), whereas aunts/uncles 
(11.6% for cases vs 6.5% for controls; P = .0161) and cousins (6.7% for cases vs 1.6% for 
controls; P < .0001) were more frequently identified around case infants.
A total of 554 of 859 (64.5%) close contacts, comprised of 163 case close contacts and 391 
control close contacts, were enrolled (Figure 1). Of identified close contacts who were not 
enrolled (n = 305), 165 (54.1%) were ineligible, 62 (20.3%) could not be reached, 65 
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(21.3%) refused or did not consent, 9 (3.0%) spoke a language other than English or 
Spanish, and 4 (1.3%) were incompetent or deceased at the time of enrollment; the 
proportion of close contacts who refused or did not consent was significantly higher among 
control infants than among case infants (3.1% for cases vs 12.2% for controls; P < .0001). 
The 554 enrolled close contacts included 371 adult close contacts ≥ 18 years of age and 183 
close contacts <18 years of age.
Of enrolled close contacts ≥ 18 years of age who were eligible to receive a dose of Tdap (n = 
371), 119 (32.1%) had record of a valid, provider-verified Tdap. Of the remaining 252 
contacts with no reported Tdap, 162 (64.3%) had follow-up completed with all listed 
providers, 60 (23.8%) reported no providers for follow-up during the interview, 14 (5.6%) 
had follow-up completed with some but not all listed providers (exhausted follow-up 
attempts with remaining providers), and 16 (6.3%) had no providers who responded after all 
attempts to contact were exhausted.
Among the 119 close contacts aged ≥ 18 years with a record of Tdap, the proportion 
vaccinated did not differ significantly between cases and controls; this finding remained 
consistent when stratified by relationship to the infant (Table 1). Overall, the median time 
since Tdap vaccination was 76 days (range, 14 days–5.8 years), and this was similar between 
cases and controls (P = .27) (Table 1). Enrolled close contacts ≥ 18 years of age who had 
received a dose of Tdap were most commonly identified as mothers of the case or control 
infant (n = 74 [62.2%]). Of these 74 vaccinated mothers, 10 control mothers and no case 
mothers were vaccinated during pregnancy. Among enrolled close contacts 11–17 years of 
age, 5 of 12 (41.7%) case close contacts and 4 of 22 (18.2%) control close contacts were 
vaccinated with Tdap (P = .31). The median time since Tdap vaccination among adolescent 
close contacts was 156 days (range, 14 days–1.7 years), and was also similar between cases 
and controls (P = .76). All 9 close contacts 11–17 years of age with a dose of Tdap were 
identified as siblings of the enrolled case or control infant.
Among the 149 close contacts <11 years of age, 121 (81%) were up to date on DTaP. The 
proportion of case close contacts (72.7%) and the proportion of control close contacts 
(84.8%) up to date on DTaP was not significantly different (P = .09).
The 371 enrolled adult close contacts comprised 172 individual potential cocoons, 71 
(41.3%) of which had complete enrollment, with all identified adult members of the 
potential cocoon enrolled. The 71 completely enrolled potential cocoons had an average of 
2.4 adult close contacts, while the remaining 101 potential cocoons with incomplete 
enrollment had an average of 3.4 adult close contacts identified and 2.0 adult close contacts 
enrolled. Of the 71 completely enrolled potential cocoons, 6 (8.5%) achieved complete 
cocooning by being fully vaccinated with Tdap; 2 of these cocoons included only a mother, 
and the other 4 cocoons were comprised of only 2 adult members. Despite small numbers, 
there was no significant difference in the proportion of fully vaccinated cocoons between 
cases (4.8%) and controls (10.0%) (P = .43). Almost half of the completely enrolled 
potential cocoons contained no adult members with a valid, provider-verified Tdap dose 
(31/71 [43.7%]); there was also no significant difference in the proportion of fully 
unvaccinated potential cocoons around cases and controls (P = .19).
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DISCUSSION
At the time of Tdap introduction in the United States, the ACIP recommendation for 
cocooning was the only recommended strategy for protecting young infants against pertussis 
in the early months of life. Despite best efforts, cocooning has proven difficult to implement 
and the effectiveness of the strategy is questionable [10–12], making it a suboptimal model 
for preventing pertussis-related morbidity and mortality in infancy. Results from our 
evaluation provide further evidence of the many challenges associated with the cocooning 
strategy. While overall Tdap coverage among enrolled adult close contacts was higher in our 
evaluation than national 2011 adult Tdap coverage estimates (12.5% coverage among adults 
19–64 years of age) [14], coverage remained low with only 32.1% of enrolled adult close 
contacts having been vaccinated. Incomplete cocooning around infant cases also occurred 
frequently in our evaluation population; of the potential cocoons where complete enrollment 
of adult close contacts was achieved, only 8% were fully vaccinated with Tdap. When 
complete cocoons could be identified, they were typically very small, comprised of only 1–2 
individuals. Unfortunately, low adult Tdap coverage and a high proportion of case and 
control infants who had no adult close contacts vaccinated left us unable to calculate the 
effectiveness of the cocooning strategy.
Our data showed that the average number of identified close contacts around infant cases 
was significantly higher than the number of identified close contacts around infant controls, 
suggesting that the risk of pertussis increases with an increased number of close contacts. 
This is consistent with published literature that has highlighted household size as a pertussis 
risk factor [15–17]. This difference between cases and controls was primarily driven by 
close contacts <18 years of age, likely mirroring the changing epidemiology of pertussis in 
the United States and the observed increase in disease among school-aged children and 
adolescents as a result of waning pertussis vaccine immunity [18, 19]. We did not, however, 
find a difference in Tdap coverage overall among individual close contacts when comparing 
the case and control infants (31.8% in case close contacts vs 32.7% in control close 
contacts). Additionally, we did not observe differences in the proportion of fully vaccinated 
cocoons (4.8% for case cocoons and 10.0% for control cocoons). Although our data were 
limited by the proportion of cases enrolled (46.7%) and the small number of potential 
cocoons where all adult close contacts were enrolled, our findings suggest that cocooning 
with Tdap had no effect on infant disease, which is consistent with much of the published 
literature [10, 20, 21].
Waning of vaccine-induced immunity, particularly among acellular-primed cohorts, has been 
well documented in the years following receipt of both DTaP and Tdap and is a major 
contributor to the current disease resurgence in the United States [22–27]. While acellular 
pertussis vaccines remain effective at preventing symptomatic disease, recent animal studies 
from a nonhuman model suggest that colonization may still occur among acellular-
vaccinated individuals [28]. Waning immunity coupled with asymptomatic pertussis 
transmission in highly vaccinated populations dramatically reduces the likelihood that 
vaccinating close contacts would provide indirect protection to infants, the basic premise of 
the cocooning strategy. In light of these challenges, the ACIP has recommended Tdap 
vaccination during the third trimester of each pregnancy as the preferred strategy for 
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pertussis prevention in infants [29]. Transplacentally transferred maternal antibodies against 
pertussis resulting from Tdap vaccination during pregnancy have been shown in the United 
Kingdom to be effective at preventing infant disease in the early months of life, offering 
important advantages to cocooning [30].
Although cocooning was the only strategy available to protect infants at the time it was 
recommended, there is now general agreement that the method is costly, is plagued with 
implementation challenges, and has uncertain effectiveness. Vaccination during pregnancy 
has been shown to be safe and effective at preventing infant disease in the early months of 
life and is being adopted by an increasing number of countries as the primary pertussis 
prevention strategy for young infants [31, 32]. Given the ongoing resurgence of pertussis in 
the United States, efforts should focus on increasing awareness and implementation of Tdap 
vaccination during pregnancy to prevent disease in infants too young to be vaccinated 
themselves.
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Figure 1. 
Study enrollment flowchart. Abbreviation: CC, close contact.
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Figure 2. 
Relationship of identified close contacts (CCs) to infant cases and controls.
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